Gene:
HBEGF
heparin-binding EGF-like growth factor

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  Diphtheria toxin receptor (heparin-binding EGF-like growth factor); heparin-binding epidermal growth factor
Alternate Symbols:  None
PharmGKB Accession Id: PA27513

Details

Cytogenetic Location: chr5 : q31.3 - q31.3
GP mRNA Boundary: chr5 : 139712428 - 139726188
GP Gene Boundary: chr5 : 139709428 - 139736188
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. EGFR Inhibitor Pathway, Pharmacodynamics
    Model non-tissue specific cancer cell displaying genes that may be involved in the treatment using epidermal growth factor receptor specific tyrosine kinase inhibitors or monoclonal antibodies.

External Pathways

Links to non-PharmGKB pathways.

  1. LPA receptor mediated events - (Pathway Interaction Database NCI-Nature Curated)
  2. Plasma membrane estrogen receptor signaling - (Pathway Interaction Database NCI-Nature Curated)

Publications related to HBEGF: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genes that mediate breast cancer metastasis to the brain. Nature. 2009. Bos Paula D, et al. PubMed

LinkOuts

Entrez Gene:
1839
OMIM:
126150
UCSC Genome Browser:
NM_001945
RefSeq RNA:
NM_001945
RefSeq Protein:
NP_001936
RefSeq DNA:
AC_000048
AC_000137
NC_000005
NT_029289
NW_001838953
NW_922784
UniProtKB:
HBEGF_HUMAN (Q99075)
Ensembl:
ENSG00000113070
GenAtlas:
HBEGF
GeneCard:
HBEGF
MutDB:
HBEGF
ALFRED:
LO045916Z
HuGE:
HBEGF
Comparative Toxicogenomics Database:
1839
ModBase:
Q99075
HumanCyc Gene:
HS03644
HGNC:
3059

Common Searches